ストックスクリーナーアプリを入手
0.31
1.64%
0.005
アフターアワーズ：
.30
-0.01
-3.23%
Cara Therapeutics Inc (CARA) 最新ニュース
Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Stamford’s Cara Therapeutics continues financial struggles; 10-employee workforce down 91% - Hartford Business Journal
Cara Therapeutics Inc. (CARA) Quarterly 10-Q Report - Quartzy
Cara: Q3 Earnings Snapshot - Houston Chronicle
Cara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rigel to Present at the Jefferies London Healthcare Conference - Quantisnow
CARGO Therapeutics, Inc. (NASDAQ:CRGX) Receives Average Rating of “Buy” from Analysts - Defense World
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Analysts - Defense World
Cara Therapeutics CEO Posner sells shares worth $1,063 - Investing.com India
Cara Therapeutics CEO Posner sells shares worth $1,063 By Investing.com - Investing.com Australia
Cara Operations (TSE:CARA) Stock Price Down 2.4% – Here’s Why - Defense World
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues - Simply Wall St
Rigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update - Quantisnow
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
CSL Limited Reports 13.5% Stake In Cara Therapeutics - XM
Truist Financial Initiates Coverage on Amentum (NYSE:AMTM) - Defense World
América Móvil (NYSE:AMX) PT Lowered to $20.80 - Defense World
Riskified Ltd. (NYSE:RSKD) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Heritage Global Inc. (NASDAQ:HGBL) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Dimensional Fund Advisors LP Purchases 55,636 Shares of VirTra, Inc. (NASDAQ:VTSI) - Defense World
Renaissance Technologies LLC Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
Opioid Use Disorder (OUD) Market Report 2024: Growth, Trends, Competitive Outlook to 2033 - WhaTech
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Financial Health Report: Cara Therapeutics Inc (CARA)’s Ratios Tell a Tale - The Dwinnex
What technical indicators reveal about CARA stock - US Post News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Quantisnow
Medical Marijuana Market Report 2024Growth, Forecast In The Latest Research - WhaTech
Cannabinoid Derived Pharmaceutical Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World
Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex
Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Large Increase in Short Interest - Defense World
Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World
G-Protein Coupled Receptors Market Growth Analysis, Trends, Share, Market Size And Forecast To 2033 - WhaTech
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
WesBanco, Inc. (NASDAQ:WSBC) Receives Consensus Rating of “Hold” from Analysts - Defense World
Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com
Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Carmat launches capital increase, stock plummets - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
Most Promising New Drugs for Hidradenitis Suppurativa, with Raj Chovatiya, MD, PhD - MD Magazine
The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News
Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex
CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle
How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News
Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews
Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex
Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR
Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Following more layoffs, Stamford’s Cara Therapeutics considers ‘strategic alternatives,’ including dissolving company - Hartford Business Journal
Analysts review Cara Therapeutics Inc’s rating - Knox Daily
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Vanguard Group Inc. Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):